Table IV.

Outcomes of de novo AML patients who at CR cleared DNMT3A R882 and all other mutations, patients who retained only a DNMT3A R882 mutation and patients who retained a DNMT3A R882 mutation and had one or more other mutations.

End point	DNMT3A CR Group 1* (n = 14)	DNMT3A CR Group 2a* (n = 30)	DNMT3A CR Group 2b* (n = 12)	P†	P‡ Gl vs. G2a	HR (95% CI) Gl vs. G2a	P‡ Gl vs. G2b	HR (95% CI) Gl vs. G2b	P‡ G2a vs. G2b	HR (95% CI) G2a vs. G2b
Complete remission, n (%)	14 (100)	27 (100)	15 (100)	–	–	–	–	–	–	–
Disease-free survival
Median, years	0·6	1·6	0·6	0·06	0·35	1·63 (0·63–4·21)	0·99	0·68 (0·24–1·95)	0·06	0·42 (0·17–1·05)
% disease-free at 3 years (95% CI)	29 (9–52)	40 (23–57)	17 (3–41)
% disease-free at 5 years (95% CI)	29 (9–52)	40 (23–57)	8 (0–31)
Overall survival
Median, years	1·3	3·8	1·3	014	0·40	1·67 (0·61–4·53)	0·99	0·78 (0·26–2·35)	014	0·47 (0·18–1·23)
% alive at 3 years (95% CI)	36 (13–59)	57 (37–72)	33 (10–59)
% alive at 5 years (95% CI)	36 (13–59)	46 (27–63)	25 (6–50)

AML, acute myeloid leukaemia; CI, confidence interval; CR, complete remission; HR, hazard ratio; n, number.

^*Group 1 (G1) is defined as patients whose DNMT3A R882 mutation cleared below the VAF cut-off of 3% in their remission sample and who had no other AML mutation. Group 2a (G2a) is defined as patients with a DNMT3A R882 mutation with a VAF >3% in their remission sample but who cleared all other AML mutations. Group 2b (G2b) is defined as patients with a DNMT3A R882 mutation with a VAF >3% in their remission sample and persistent or newly acquired other AML mutations.

^†Overall P-value pertaining to comparison of all three patients groups.

^‡Pairwise comparisons are adjusted from multiple comparisons using the Bonferroni method (Westfall et al, 1999).